Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin-2

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 711-712

  Elkadi, Dahlia ^a,b   Wiernik, Peter H ^c   Tong, Tommy R ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Cancer Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

CASE REPORT; HUMAN; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; INTERLEUKIN-2; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PREDNISOLONE; VINCRISTINE;

EID: 77956462942     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21604     Document Type: Article

References (16)

1. Baselmans AH, Koten JW, Battermann JJ, et al. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002;51:492-498.
2. Lopes de Menezes DE, Denis-Mize K, Tang Y, et al. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin's lymphoma. J Immunother 2007;30:64-74. (Pubitemid 46052204)
3. Gisselbrecht C, Maraninchi D, Pico JL, et al. Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 1994;83:2081-2085.
4. Dillman DO, Church C, Barth NM, et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm 1997;12:243-248.
5. Kiss TL, Spaner D, Daly AS, et al. Complete remission of tumor with interleukin-2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. Br J Haematol 2003;120:523-525.
6. Khan KD, Emmanouilides C, Benson DM Jr, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:7046-7053.
7. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin Cancer Res 2004;10:6101-6110.
8. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer 1998;83:2099-2104. (Pubitemid 28525391)
9. Kojiro N, Ishihara H, Ito M, et al. Intrapleural administration of recombinant interleukin-2 in a patient with pleural effusion due to non-Hodgkin's lymphoma. Nihon Kyobu Shikkan Gakkai Zasshi 1989;27:954-959.
10. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 2002;16(Suppl 13):4-10.
11. Dutcher JP, Gaynor ER, Boldt DH, et al. Phase II study of high dose continous infusion interleukin-2 with lymphokine-activated killer cells in metastatic melanoma. J Clin Oncol 1991;9:641-648.
12. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cells therapy of solid tumors, analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-498.
13. Wiernik PH, Dutcher JP, Todd M, et al. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 1994;47:41-44.
14. Schliemann C, Palumbo A, Zuberbucombining double acute accenthler K, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275-2283.
15. Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res 2000;20:2103-2105.
16. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828-834.